West Pharmaceutical Services, Inc.
WST
$302.40
-$9.67-3.10%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 21.05% | 7.51% | 7.73% | 9.17% | 0.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.05% | 7.51% | 7.73% | 9.17% | 0.37% |
| Cost of Revenue | 17.68% | 5.45% | 5.83% | 4.34% | 0.19% |
| Gross Profit | 27.81% | 11.07% | 11.18% | 19.09% | 0.74% |
| SG&A Expenses | 14.90% | 29.05% | 23.44% | 13.86% | -0.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -833.33% | -- | -50.00% | -- | 0.00% |
| Total Operating Expenses | 16.21% | 9.32% | 8.38% | 5.92% | -0.09% |
| Operating Income | 42.42% | 1.40% | 5.46% | 23.55% | 2.47% |
| Income Before Tax | 61.11% | -0.90% | 3.33% | 21.62% | -13.52% |
| Income Tax Expenses | 85.48% | -9.51% | 4.94% | 37.90% | 46.95% |
| Earnings from Continuing Operations | 54.57% | 1.54% | 2.94% | 18.42% | -22.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.57% | 1.54% | 2.94% | 18.42% | -22.12% |
| EBIT | 42.42% | 1.40% | 5.46% | 23.55% | 2.47% |
| EBITDA | 35.45% | 4.09% | 5.75% | 19.60% | 4.65% |
| EPS Basic | 55.64% | 2.10% | 3.80% | 19.73% | -21.04% |
| Normalized Basic EPS | 41.31% | 2.82% | 6.65% | 25.25% | 2.21% |
| EPS Diluted | 56.10% | 2.08% | 3.78% | 20.53% | -20.65% |
| Normalized Diluted EPS | 41.49% | 3.10% | 6.94% | 25.92% | 2.62% |
| Average Basic Shares Outstanding | -0.69% | -0.55% | -0.82% | -1.10% | -1.36% |
| Average Diluted Shares Outstanding | -0.82% | -0.82% | -1.09% | -1.63% | -1.75% |
| Dividend Per Share | 4.76% | 4.76% | 5.00% | 5.00% | 5.00% |
| Payout Ratio | -0.33% | 0.02% | 0.01% | -0.13% | 0.33% |